PYPan-Chyr Yang

Pan-Chyr Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pan-Chyr Yang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer

    by Kuan-Yu Chen, Yuan-Chii Gladys Lee, Jin-Mei Lai, Yih-Leong Chang, Yung-Chie Lee, Chong-Jen Yu, Chi-Ying F. Huang, Pan-Chyr Yang


  • Elevation of telomerase activity positively correlates to poor prognosis of patients with non-small cell lung cancer

    by Kuan-Yu Chen, Li-Na Lee, Chong-Jen Yu, Yung-Chie Lee, Sow-Hsong Kuo, Pan-Chyr Yang


    • 1 July 2006
      • Vol. 1  (6) , 520-5

    Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.

    by Gee-Chen Chang, Chun-Ming Tsai, Kun-Chieh Chen, Chong-Jen Yu, Jin-Yuan Shih, Tsung-Ying Yang, Ching-Pei Lin, Jeng-Yuan Hsu, Chao-Hua Chiu, Reury-Perng Perng, et al.

    Gender, smoking history, adenocarcinoma histology, performance status, and East Asian ethnicity were predictive factors of gefitinib response in previous analysis. However, these factors tend to be correlated with each other; it is not clear whether gender, smoking history, and adenocarcinoma histology were all independent predictors for response in East Asian populations. Tumor response, survival and predictive factors of gefitinib response of advanced non-small cell lung cancer patients treated between May of 2002 and November of 2004 were collected retrospectively from three medical centers in Taiwan. Univariate and multivariate logistic regression models were used to test potential predictive factors associated with response to gefitinib. Overall survivals between groups with different predictive factors were compared by log-rank tests. Multivariate analyses were performed to identify factors that independently predict for survival. A total of 428 patients were analyzed. The median follow-up duration for living patients was 19.5 months (range, 10.2-39.9). Objective tumor response was observed in 114 patients (26.6%, 95% confidence interval [CI]: 22.4%-30.8%) and disease stabilization in 129 patients (30.2%). Response rate was statistically significant higher in adenocarcinoma, good performance status, and chemonaive patients in multivariate analysis. The median survival was 7.4 months (95% CI: 5.8-9.0) and 1-year survival was 34.3% (95% CI: 29.0%-38.0%). Significant independent predictive factors associated with longer survival in multivariate analysis were good performance status (p < 0.001) and responsiveness to gefitinib (p < 0.001). In 286 chemotherapy-treated patients, the response rate was 22.7%. Median and 1-year survival was 7.9 months and 36.7%, respectively. Good performance status was predictive of tumor response (p < 0.001) and better survival (p < 0.001) in multivariate analysis. Response to gefitinib was predictive of better survival (p < 0.001). Gender and smoking status were not, but good performance status (PS), no previous chemotherapy, and adenocarcinoma histology were independent predictive factors in multivariate analysis for gefitinib response in Taiwanese advanced non-small cell lung cancer population. In patients previously treated with chemotherapy, only good PS was an independent predictor for tumor response in multivariate analysis.


  • Open Access

    Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma

    by Kuan‐Yu Chen, Chia‐Hsuin Chang, Chong‐Jen Yu, Sow‐Hsong Kuo, Pan‐Chyr Yang

    BACKGROUND: The results from previous studies suggested that the clinical characteristics and outcomes of patients with lung carcinoma vary between gender and age groups. The objective of the current study was to assess the trend in the evolution of the histologic types in Taiwan and to compare the outcomes of patients with lung carcinoma between different gender and age groups.METHODS: Patients with primary lung carcinoma were identified through the cancer registry system. Clinical records were reviewed and analyzed for age, gender, disease stage, histology, treatment modalities, and survival. A multivariate analysis using a Cox proportional hazards model was applied for gender, age (by decade), histologic type, disease stage, and treatment modality.RESULTS: Between 1991–1999, 2714 patients with histologically or cytologically proven lung carcinoma were included. Adenocarcinoma was the major cell type of lung carcinoma (52.5%), with a significant trend toward an increase in adenocarcinoma during the study period. A significantly high percentage of adenocarcinoma was demonstrated in female patients (73.5%), who also had better survival compared with male patients (P = 0.002), especially in the group age 50–69 years. Patients age < 40 years also had a poor prognosis, which was worse compared with the prognosis for patients age 40–59 years. patients who had adenocarcinoma had a better survival rate compared with patients who had other histologic types (relative risk, 0.78; 95% confidence interval, 0.69–0.87).CONCLUSIONS: Adenocarcinoma was predominant in female patients and emerged as a greater problem than other histologic types in Taiwan, potentially raising the importance of studies regarding the benefit of population diversity in new antitumor therapies, such as gefitinib. Female patients with lung carcinoma had a better prognosis than male patients in the group age 50–69 years, warranting further studies on potential prognostic factors associated with middle age, such as hormone status. Cancer 2005. © 2005 American Cancer Society.


    • 1 September 2004
      • Vol. 103  (9) , 671-7

    Drug resistance pattern of Mycobacterium tuberculosis in a university hospital in Taiwan, 1998-2002.

    by Yuang-Shuang Liaw, Po-Ren Hsueh, Chong-Jen Yu, Shu-Kuang Wang, Pan-Chyr Yang, Kwen-Tay Luh

    During 1998-2002, most specialized tuberculosis (TB) hospitals in Taiwan were closed; as a result, more TB patients are being managed in general hospital settings. This study investigated the prevalence, patterns and risk factors of drug-resistant Mycobacterium tuberculosis at a university hospital in the 5 years after decentralization of the TB administrative and clinical control infrastructure which occurred during the implementation of the national health insurance system in Taiwan. A total of 1411 initial isolates of M. tuberculosis from specimens collected during January 1998 through December 2002 were tested for drug susceptibility of first-line anti-TB drugs using the agar proportional method. The numbers of newly diagnosed culture-positive TB patients increased from 139 in 1998 to 380 in 2002. The drug resistance pattern of M. tuberculosis among these isolates was as follows: 268 (19.0%) strains were resistant to isoniazid, 86 (6.1%) to rifampin, 221 (15.7%) to ethambutol, 141 (10.0%) to streptomycin, and 430 (30.5%) to 1 of these 4 drugs. Multidrug resistance (MDR), i.e., resistance to at least rifampin and isoniazid, was observed in 72 isolates (5.1%). Of the 1411 patients, isolates from patients with age < 65 years had a higher multiple drug resistance rate than those from patients with age > or = 65 years (57/781, 7.3% vs 15/630, 2.4%; p < 0.001). In the analysis of risk factors for MDR, patients with MDR isolates had a significantly higher incidence of previous TB history, anti-TB therapy, longer duration of symptoms, cavitary lesions in chest X-ray, and mortality. A dramatic increase in cases of TB among patients treated at this university hospital was seen after the decentralization of the TB control infrastructure in Taiwan. The prevalence of drug resistance in isolates from culture-positive TB patients was 30.5% and the prevalence of MDR was 5.1%.


    • 1 November 2003
      • Vol. 102  (11) , 788-92

    Continuous lateral rotational therapy in the medical intensive care unit.

    by Jann-Yuan Wang, Pao-Yu Chuang, Chun-Ju Lin, Chong-Jen Yu, Pan-Chyr Yang

    The efficacy of continuous lateral rotational therapy (CLRT) for mechanically ventilated patients is not well established. This study investigated the effect of CLRT on gas exchange and the incidence of ventilator-associated pneumonia (VAP) in mechanically ventilated patients in a medical intensive care unit (ICU). Thirty five mechanically ventilated patients in a medical ICU received CLRT for 5 days, while 35 control patients matched for age, gender, cause of respiratory failure, and admission Acute Physiology and Chronic Health Evaluation (APACHE) score, received routine positional change. The results of blood gas analysis, incidence of VAP, findings on chest radiograph, length of ICU stay, and sputum characteristics were recorded. Greater improvement in oxygenation index (the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen) was noted in the patients who received CLRT (31 +/- 42 vs 6 +/- 76, p = 0.03). Patients who received CLRT also had lower VAP incidence (0 vs 5, p < 0.001), were more likely to have improvement in pulmonary infiltrates (17 vs 12, p = 0.04) and had shorter ICU stay (22 +/- 8 days vs 27 +/- 12 days, p = 0.09). The ICU discharge status (dead, ventilator dependent, alive) was not significantly different between the 2 groups. Mechanically ventilated patients in the medical ICU who received CLRT had improved oxygenation and reduced incidence of VAP compared to controls.


    • 1 September 2003
      • Vol. 102  (9) , 601-6

    Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan.

    by Lu-Cheng Kuo, Chong-Jen Yu, Li-Na Lee, Jiun-Ling Wang, Hao-Chien Wang, Po-Ren Hsueh, Pan-Chyr Yang

    The number of infections caused by Acinetobacter baumannii has increased in recent years and the emergence of pandrug-resistant A. baumannii (PDRAB) has been observed in Taiwan. The aim of this study was to evaluate the clinical features and outcomes of patients with bacteremia due to PDRAB. From January 1999 to April 2002, 30 patients with PDRAB bacteremia were treated. We analyzed the clinical characteristics of these patients, including gender, underlying diseases, clinical manifestations, antibiotic treatment, and outcome. Bacteremia developed an average of 33 days after hospitalization and was hospital acquired in all cases. The source of bacteremia was identified in 19 patients (63.3%) and was most commonly from the respiratory tract. The overall mortality was 60% (18 patients). Among these, the cause of death was directly related to PDRAB bacteremia in 12. Underlying heart disease, shock, resuscitation, acute respiratory distress syndrome, mechanical ventilation, and multiple organ dysfunction score (MODS) were significant predictors of mortality after the development of PDRAB bacteremia. No specific antimicrobial therapy appeared to be effective. Clinical outcomes of patients with PDRAB bacteremia were related to the medical conditions of the patients at the time of development of bacteremia and could be predicted by the MODS. The only way to limit the spread is through strict preventive measures for nosocomial infection and antibiotic control.


    • 1 August 2003
      • Vol. 102  (8) , 534-8

    Trends in asthma mortality in Taiwan, 1981-2000.

    by Lu-Cheng Kuo, Wen-Yi Shau, Pan-Chyr Yang, Sow-Hsong Kuo

    The prevalence and mortality rates of asthma in many countries have increased in the past 2 decades. The purpose of this study was to determine the trends of asthma mortality in Taiwan from 1981 through 2000. Data from the National Health Statistics for Taiwan identifying asthma [International Classification of Disease (ICD)-9 code 493] as the underlying cause of death were collected. Age-specific and age-adjusted mortality rates of asthma were calculated and the 20-year trends were analyzed. The crude mortality rate of asthma decreased from 8.17 to 4.53 per 100,000 general population, and the age-adjusted mortality rate decreased from 8.17 to 2.37 per 100,000 during the 20-year period. This trend of decreasing mortality was most obvious for age groups older than 35 years, i.e., from 4.05 to 1.20 per 100,000 in those aged 35 to 54 years and from 47.43 to 13.44 per 100,000 in those aged 55 to 74 years. The mortality rate for asthma in those aged 15 to 34 years remained the same, around 0.40 to 0.35 per 100,000 population. For those below 15 years of age, the mortality rates for asthma fluctuated between 0.30 and 0.10 per 100,000 population. The mortality rate of asthma has steadily decreased in Taiwan in the past 20 years, especially in the age groups above 35 years.


    • 1 July 2003
      • Vol. 9  (7) , 2807-16

    Tumor-associated antigen L6 and the invasion of human lung cancer cells.

    by Yu-Rong Kao, Jin-Yuan Shih, Wei-Chun Wen, Ya-Ping Ko, Bing-Mae Chen, Yi-Lin Chan, Yi-Wen Chu, Pan-Chyr Yang, Cheng-Wen Wu, Steve R Roffler

    Metastasis is a coordinated process that depends on the interaction of cancer cells with the tumor microenvironment. Members of the transmembrane-4 superfamily (TM4SF) of surface proteins have been implicated in the regulation of cancer cell metastasis, and the expression of several TM4SF members on tumor cells is inversely correlated with patient prognosis. The tumor-associated antigen L6 (TAL6), a distant member of the TM4SF, is expressed on most epithelial cell carcinomas and is a target for antibody-mediated therapy. We examined whether TAL6 may play a role in cancer metastasis by using an established series of human lung carcinoma cell lines (CL1-0 to CL1-5) that exhibit increasing invasiveness in vitro and in vivo. We found that TAL6 expression correlated with the in vitro invasiveness of CL lung carcinoma cells (r(2) = 0.98) and human carcinoma cells (r(2) = 0.69). Forced expression of TAL6 on CL1-0 lung carcinoma cells significantly increased their in vitro invasiveness and decreased the survival of SCID mice in an experimental metastasis model. Specific antibody against TAL6 (monoclonal antibody L6) significantly reduced the migration and invasiveness of CL1-5 lung carcinoma cells. The effects of monoclonal antibody L6 on CL1-5 invasion required clustering of TAL6 on the cell surface. Real-time reverse transcription-PCR of lung cancer specimens showed that increased expression of TAL6 was significantly associated with early postoperative relapse (P = 0.034) and shorter survival (P = 0.025) in squamous cell lung cancer patients. Thus, TAL6 appears to be involved in cancer invasion and metastasis.